Loading
A phase 2 trial of cemiplimab in lung cancer, run by Georgetown University, now recruiting.
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features is a phase 2, interventional study registered as NCT06449313 by Georgetown University, with a registry enrolment figure of 21 participants, started 2026-08 and due to reach its primary completion in 2027-12. Interventions recorded: Cemiplimab-Rwlc. Conditions listed: Non-small Cell Lung Cancer Stage III. Primary outcome: Pathologic complete response (pCR) rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed stage 3 Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) that meets one of the below criteria:". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Unresectable stage III non-small-cell lung cancer, Cemiplimab, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Unresectable stage III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/